Navigation Links
Dynasil Regains Compliance with NASDAQ Listing Requirements
Date:1/7/2014

WATERTOWN, Mass., Jan. 7, 2014 /PRNewswire/ -- Dynasil Corporation of America ("Dynasil" or the "Company") (NASDAQ: DYSL), a developer of sensing, detection and analysis technology for homeland security, medical and industrial applications, announced today that it has regained compliance with the $1.00 minimum bid price requirement for continued listing on the NASDAQ Capital Market.

As previously announced, on March 26, 2013, NASDAQ notified the Company that the closing bid price of Dynasil's common stock had fallen below $1.00 per share over the previous 30 consecutive business days and, as a result, the Company was not in compliance with the minimum bid requirement. 

On January 7, 2014, NASDAQ notified the Company that the closing bid price of its common stock had been $1.00 per share or greater for 10 consecutive business days.  Accordingly, Dynasil has regained compliance and the NASDAQ now considers the matter closed.

About Dynasil
Dynasil Corporation of America (NASDAQ: DYSL) develops and manufactures optical detection and analysis technology and components for the homeland security, medical and industrial markets.  Combining world-class expertise in research and materials science with extensive experience in manufacturing and product development, Dynasil is commercializing products including dual-mode radiation detection solutions for Homeland Security and commercial applications and sensors for non-destructive testing.  Dynasil has an impressive and growing portfolio of issued and pending U.S. patents.  The Company is based in Watertown, Massachusetts, with additional operations in Mass., Minn., NY, NJ and the United Kingdom. More information about the Company is available at www.dynasil.com.

Contact:
Patty Kehe
Corporate Secretary
Dynasil Corporation of America
Phone: (617) 668-6855
pkehe@dynasil.com 

 


'/>"/>
SOURCE Dynasil Corporation of America
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. Dynasils RMD Subsidiary Awarded $4 Million in Technology Development Grants by U.S. Department of Energy
2. Fonetic Adds Voice Biometrics To Its Award-Winning Dodd-Frank Record Keeping Compliance and Trade Reconstruction Solution
3. NASDAQ Sets Ex-Dividend Date for Aware, Inc.s Special Cash Dividend of $1.80 Per Share
4. Enlisting cells protein recycling machinery to regulate plant products
5. Animal welfare scientists reveal infrequent and inconsistent acceptance of existing data by EPA to satisfy endocrine disruptor testing requirements
6. NREL report firms up land-use requirements of solar
7. Fish oil added to yogurt may help consumers meet daily nutritional requirements
8. Energy requirements make Antarctic fur seal pups vulnerable to climate change
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:3/29/2016)... RATON, Florida , March 29, 2016 ... or the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are ... DNA in ink used in a variety of writing ... theft. Buyers of originally created collectibles from athletes on ... through forensic analysis of the DNA. ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... --  EpiBiome , a precision microbiome engineering company, today ... from Silicon Valley Bank (SVB). The financing will allow ... drug development efforts, as well as purchase additional lab ... been an incredible strategic partner to us – one ... provide," said Dr. Aeron Tynes Hammack , EpiBiome,s ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only ... Center and will showcase its product’s latest features from June 26 to June ... scientific poster on Disrupting Clinical Trials in The Cloud during the conference. ...
(Date:6/23/2016)... June 23, 2016 ReportsnReports.com ... report to its pharmaceuticals section with historic and ... and much more. Complete report on ... pages, profiling 15 companies and supported with 261 ... http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . The Global Cell ...
Breaking Biology Technology: